1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Turkey Pharmaceuticals and Healthcare Report Q1 2016

Turkey Pharmaceuticals and Healthcare Report Q1 2016

  • January 2016
  • -
  • Business Monitor International
  • -
  • 97 pages

Includes 3 FREE quarterly updates

BMI View: A strong health care sector and more certain drug pricing policy will drive pharmaceuticalsales in value terms over the next 10 years and improve the commercial opportunities for pharmaceuticalmanufacturers Despite this positive development, cost containment measures will remain a risk, as will thepolitical situation with neighbouring Syria and nearby Russia

Headline Expenditure Projections

- Pharmaceuticals: TRY1872bn (USD856bn) in 2014 to TRY2081bn (USD738bn) in 2015; +111% inlocal currency and -138% US dollar terms Forecast unchanged in local currency and down in USdollars compared with previous quarter due to revised exchange rate expectations
- Healthcare: TRY9578bn (USD4378bn) in 2014 to TRY10717bn (USD3801bn) in 2015; +119% inlocal currency and -132% US dollar terms Forecast unchanged in local currency and down in USdollars compared with previous quarter due to revised exchange rate expectations

Table Of Contents

Turkey Pharmaceuticals and Healthcare Report Q1 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Turkey 2013-2019) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Turkey 2011-2019) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Turkey 2011-2019) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Turkey 2011-2019) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Turkey 2011-2019) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Turkey 2011-2019) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Turkey 2011-2019) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Turkey 2011-2019) 24
OTC Medicine Market Forecast 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Turkey 2011-2019) 27
Pharmaceutical Trade Forecast 28
Table: Pharmaceutical Trade Data And Forecasts (Turkey 2013-2019) 30
Table: Pharmaceutical Trade Data And Forecasts local currency (Turkey 2013-2019) 30
Industry Risk/Reward Index 31
Central And Eastern Europe Risk/Reward Index - Q1 2016 31
Turkey Risk/Reward Index 38
Rewards 38
Risks 39
Regulatory Review 41
Intellectual Property Regime 42
Market Access Issues 45
Pricing Regime 47
Table: Turkish Pharmaceutical Pricing Decrees 48
Reimbursement Regime 49
Table: Pharmacist Discount Related To Annual Sales Revenue (VAT Excluded) 51
Market Overview 52
Market Overview 52
Epidemiology 53
Healthcare Sector 54
Health Insurance 55
Healthcare Infrastructure 55
Healthcare Financing 57
Table: Healthcare Resources (Turkey 2009-2014) 58
Table: Healthcare Personnel (Turkey 2009-2014) 58
Table: Healthcare Activity (Turkey 2009-2014) 59
Research and Development 59
Clinical Trials 61
Competitive Landscape 62
Pharmaceutical Sector 62
Research-Based Industry 63
Generic Drugmakers 64
Company Activity 66
Table: Multinational Market Activity 66
Pharmaceutical Distribution 67
Pharmaceutical Retail 68
Company Profile 70
Abdi ?brahim 70
EastPharma (Deva) 74
Eczaciba?i Healthcare 77
Mustafa Nevzat Ilac Sanayi (MN) Pharmaceuticals 80
Sanovel Pharmaceuticals 83
Demographic Forecast 86
Table: Population Headline Indicators (Turkey 1990-2025) 87
Table: Key Population Ratios (Turkey 1990-2025) 87
Table: Urban/Rural Population and Life Expectancy (Turkey 1990-2025) 88
Table: Population By Age Group (Turkey 1990-2025) 88
Table: Population By Age Group % (Turkey 1990-2025) 89
Glossary 91
Methodology 93
Pharmaceutical Expenditure Forecast Model 93
Healthcare Expenditure Forecast Model 93
Notes On Methodology 94
Risk/Reward Index Methodology 95
Index Overview 96
Table: Pharmaceutical Risk/Reward Index Indicators 96
Indicator Weightings 97

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.